BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2022 2:23:07 PM | Browse: 237 | Download: 375
 |
Received |
|
2021-09-06 17:40 |
|
Peer-Review Started |
|
2021-09-06 17:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-04 22:12 |
|
Revised |
|
2021-12-05 10:00 |
|
Second Decision |
|
2022-02-09 06:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-02-10 16:32 |
|
Articles in Press |
|
2022-02-10 16:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-01-17 03:27 |
|
Typeset the Manuscript |
|
2022-02-23 08:47 |
|
Publish the Manuscript Online |
|
2022-03-15 14:23 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Almurtada Razok, Fateen Ata, Sara Mohamed Ibrahim Ahmed and Dabia Hamad S H Al Mohanadi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fateen Ata, BSc, MBBS, MD, Doctor, Department of Internal Medicine, Hamad Medical Corporation, Al Rayyan Street, Bin Omran Area, Al Rayyan, Doha 3050, Qatar. docfateenata@gmail.com |
| Key Words |
Euglycemic diabetic ketoacidosis; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus; Empagliflozin |
| Core Tip |
With a steady surge in the prescription of sodium-glucose co-transporter 2 inhibitors (SGLT2-i) in medical conditions including type 2 diabetes mellitus (DM), type 1 DM, and heart failure, there are increasingly reported cases of euglycemic diabetic ketoacidosis (EDKA) with their use. EDKA in the context of SGLT2-i use is reported in various patients with different precipitating factors, some even with no inciting event. One of the rarely reported inciting events is stroke. Another aspect of SGLT2-i induced EDKA which remains relatively less understood is the time of initiation of the drug to the development of EDKA. In our patient, severe EDKA developed within 4 d of empagliflozin initiation, necessitating intensive care and discontinuation of empagliflozin, resulting in complete recovery regarding the EDKA. |
| Publish Date |
2022-03-15 14:23 |
| Citation |
Razok A, Ata F, Ahmed SMI, Al Mohanadi DHSH. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World J Diabetes 2022; 13(3): 272-274 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i3/272.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i3.272 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
